Kangzhe Pharmaceuticals (00867): The independently developed innovative drug complement factor B inhibitor CMS-D017 has obtained the approval notice for clinical trials of age-related macular degeneration indications.

News from the Securities Times APP, Kangzhe Pharmaceutical (00867) announced that on July 15, 2026, the innovative drug complement factor B inhibitor CMS-D017 capsule (CMS-D017 or product) independently developed by the group has obtained the drug clinical trial approval notification issued by the National Medical Products Administration (NMPA) of China. NMPA has agreed for the group to conduct clinical trials to evaluate the safety and efficacy of CMS-D017 in the treatment of age-related macular degeneration (AMD) indications.